Evidence map›Paper›PMID 40126245›Full record

ArticleMethods and protocols2025

Whole-Exome Sequencing Followed by dPCR-Based Personalized Genetic Approach in Solid Organ Transplantation: A Study Protocol and Preliminary Results.

Mirgul Bayanova, Aidos Bolatov, Dias Malik, Aida Zhenissova, Aizhan Abdikadirova, Malika Sapargaliyeva, Lyazzat Nazarova, Gulzhan Myrzakhmetova, Svetlana Novikova, Aida Turganbekova and 1 more

Abstract read
In one paragraph

Article in Methods and protocols, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mirgul BayanovaGenetic Unit, Department of Laboratory Medicine, Pathology and Genetics, "University Medical Center" Corporate Fund, Astana 010000, Kazakhstan.ORCID 0000-0002-6167-5357
Aidos BolatovGenetic Unit, Department of Laboratory Medicine, Pathology and Genetics, "University Medical Center" Corporate Fund, Astana 010000, Kazakhstan.ORCID 0000-0002-5390-4623
Dias MalikGenetic Unit, Department of Laboratory Medicine, Pathology and Genetics, "University Medical Center" Corporate Fund, Astana 010000, Kazakhstan.
Aida ZhenissovaGenetic Unit, Department of Laboratory Medicine, Pathology and Genetics, "University Medical Center" Corporate Fund, Astana 010000, Kazakhstan.
Aizhan AbdikadirovaGenetic Unit, Department of Laboratory Medicine, Pathology and Genetics, "University Medical Center" Corporate Fund, Astana 010000, Kazakhstan.
Malika SapargaliyevaGenetic Unit, Department of Laboratory Medicine, Pathology and Genetics, "University Medical Center" Corporate Fund, Astana 010000, Kazakhstan.
Lyazzat NazarovaGenetic Unit, Department of Laboratory Medicine, Pathology and Genetics, "University Medical Center" Corporate Fund, Astana 010000, Kazakhstan.
Gulzhan MyrzakhmetovaClinical Academic Department of Cardiology, "University Medical Center" Corporate Fund, Astana 010000, Kazakhstan.
Svetlana NovikovaClinical Academic Department of Cardiac Surgery, "University Medical Center" Corporate Fund, Astana 010000, Kazakhstan.ORCID 0000-0001-8161-7712
Aida TurganbekovaHLA-Laboratory, Scientific-Production Center of Transfusiology, Astana 010000, Kazakhstan.
Yuriy PyaClinical Academic Department of Cardiac Surgery, "University Medical Center" Corporate Fund, Astana 010000, Kazakhstan.

Funding

Committee of Science of the Ministry of Science and Higher Education of the Republic of Kazakhstan BR21882206
6 · The paper itself

Abstract

Genetic profiling and molecular biology methods have made it possible to study the etiology of the end-stage organ disease that led to transplantation, the genetic factors of compatibility and tolerance of the transplant, and the pharmacogenetics of immunosuppressive drugs and allowed for the development of monitoring methods for the early assessment of allograft rejection. This study aims to report the design and baseline characteristics of an integrated personalized genetic approach in solid organ transplantation, including whole-exome sequencing (WES) and the monitoring of dd-cfDNA by dPCR. Preliminary results reported female recipients with male donors undergoing two pediatric and five adult kidney and three heart transplantations. WES revealed a pathogenic mutation in

Indexed as

clinical utilitydd-cfDNAgenetic testingpharmacogeneticstransplantationwhole-exome sequencing

Identifiers

PMID40126245
PMCPMC11932258

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.